Global Human Rabies Immunoglobulin (IM) Market Research Report 2022 Professional Edition
- Published Date : 04-04-2022
- Pages : 140
- Report Id : 33343
- Categories : Healthcare
The global Human Rabies Immunoglobulin (IM) market was valued at 27.93 Million USD in 2022 and will grow with a CAGR of 7.34% from 2022 to 2028, based on Stats and Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient`s passive immunization. The classification according to the material of Human Rabies Immunoglobulin (IM) includes ERIG, HRIG, and the proportion of HRIG in 2017is about 86.7%, and the proportion is in increasing trend from 2013 to 2017. For ERIGs, the dosage is 40 IU per kg body weight subject to a maximum of 3000 IU. For HRIGs, the dosage is 20 IU per kg body weight subject to a maximum of 1500 IU. Human Rabies Immunoglobulin (IM) is widely used for the Category II Exposure and Category III Exposure, the most proportion of Human Rabies Immunoglobulin (IM) is used for Category III Exposure, and the proportion in 2017 is about 82.6%. China is the largest sales place, with a sales market share nearly 61.4% in 2017, because of the population. North America enjoys 4.3% market share.
By Market Verdors:
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
By Types:
ERIG
HRIG
By Applications:
Category II Exposure
Category III Exposure
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2017-2028 & Sales with a thorough analysis of the market s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2017-2028. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Human Rabies Immunoglobulin (IM) Revenue
1.4 Market Analysis by Type
1.4.1 Global Human Rabies Immunoglobulin (IM) Market Size Growth Rate by Type: 2022 VS 2028
1.4.2 ERIG
1.4.3 HRIG
1.5 Market by Application
1.5.1 Global Human Rabies Immunoglobulin (IM) Market Share by Application: 2017-2028
1.5.2 Category II Exposure
1.5.3 Category III Exposure
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Human Rabies Immunoglobulin (IM) Market
1.8.1 Global Human Rabies Immunoglobulin (IM) Market Status and Outlook (2017-2028)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Human Rabies Immunoglobulin (IM) Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Human Rabies Immunoglobulin (IM) Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Human Rabies Immunoglobulin (IM) Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Human Rabies Immunoglobulin (IM) Sales Volume Market Share by Region (2017-2022)
3.2 Global Human Rabies Immunoglobulin (IM) Sales Revenue Market Share by Region (2017-2022)
3.3 North America Human Rabies Immunoglobulin (IM) Sales Volume
3.3.1 North America Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.3.2 North America Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 East Asia Human Rabies Immunoglobulin (IM) Sales Volume
3.4.1 East Asia Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.4.2 East Asia Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.5.1 Europe Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.5.2 Europe Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 South Asia Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.6.1 South Asia Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.6.2 South Asia Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.7.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.7.2 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.8 Middle East Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.8.1 Middle East Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.8.2 Middle East Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.9 Africa Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.9.1 Africa Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.9.2 Africa Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.10 Oceania Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.10.1 Oceania Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.10.2 Oceania Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.11 South America Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.11.1 South America Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.11.2 South America Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.12 Rest of the World Human Rabies Immunoglobulin (IM) Sales Volume (2017-2022)
3.12.1 Rest of the World Human Rabies Immunoglobulin (IM) Sales Volume Growth Rate (2017-2022)
3.12.2 Rest of the World Human Rabies Immunoglobulin (IM) Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
4 North America
4.1 North America Human Rabies Immunoglobulin (IM) Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Human Rabies Immunoglobulin (IM) Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Human Rabies Immunoglobulin (IM) Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Human Rabies Immunoglobulin (IM) Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Human Rabies Immunoglobulin (IM) Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Human Rabies Immunoglobulin (IM) Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Human Rabies Immunoglobulin (IM) Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Human Rabies Immunoglobulin (IM) Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Human Rabies Immunoglobulin (IM) Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Human Rabies Immunoglobulin (IM) Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Human Rabies Immunoglobulin (IM) Sales Volume Market Share by Type (2017-2022)
14.2 Global Human Rabies Immunoglobulin (IM) Sales Revenue Market Share by Type (2017-2022)
14.3 Global Human Rabies Immunoglobulin (IM) Sales Price by Type (2017-2022)
15 Consumption Analysis by Application
15.1 Global Human Rabies Immunoglobulin (IM) Consumption Volume by Application (2017-2022)
15.2 Global Human Rabies Immunoglobulin (IM) Consumption Value by Application (2017-2022)
16 Company Profiles and Key Figures in Human Rabies Immunoglobulin (IM) Business
16.1 CSL Behring
16.1.1 CSL Behring Company Profile
16.1.2 CSL Behring Human Rabies Immunoglobulin (IM) Product Specification
16.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.2 Grifols
16.2.1 Grifols Company Profile
16.2.2 Grifols Human Rabies Immunoglobulin (IM) Product Specification
16.2.3 Grifols Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.3 Sanofi
16.3.1 Sanofi Company Profile
16.3.2 Sanofi Human Rabies Immunoglobulin (IM) Product Specification
16.3.3 Sanofi Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.4 Sichuan Yuanda Shuyang
16.4.1 Sichuan Yuanda Shuyang Company Profile
16.4.2 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Specification
16.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.5 CNBG
16.5.1 CNBG Company Profile
16.5.2 CNBG Human Rabies Immunoglobulin (IM) Product Specification
16.5.3 CNBG Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.6 Kamada
16.6.1 Kamada Company Profile
16.6.2 Kamada Human Rabies Immunoglobulin (IM) Product Specification
16.6.3 Kamada Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.7 CBPO
16.7.1 CBPO Company Profile
16.7.2 CBPO Human Rabies Immunoglobulin (IM) Product Specification
16.7.3 CBPO Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.8 Shuanglin Bio
16.8.1 Shuanglin Bio Company Profile
16.8.2 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Specification
16.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.9 Weiguang Bio
16.9.1 Weiguang Bio Company Profile
16.9.2 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Specification
16.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.10 Shanghai RAAS
16.10.1 Shanghai RAAS Company Profile
16.10.2 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Specification
16.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.11 Bharat Serum
16.11.1 Bharat Serum Company Profile
16.11.2 Bharat Serum Human Rabies Immunoglobulin (IM) Product Specification
16.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.12 VINS
16.12.1 VINS Company Profile
16.12.2 VINS Human Rabies Immunoglobulin (IM) Product Specification
16.12.3 VINS Human Rabies Immunoglobulin (IM) Production Capacity, Revenue, Price and Gross Margin (2017-2022)
17 Human Rabies Immunoglobulin (IM) Manufacturing Cost Analysis
17.1 Human Rabies Immunoglobulin (IM) Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Human Rabies Immunoglobulin (IM)
17.4 Human Rabies Immunoglobulin (IM) Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Human Rabies Immunoglobulin (IM) Distributors List
18.3 Human Rabies Immunoglobulin (IM) Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Human Rabies Immunoglobulin (IM) (2017-2028)
20.2 Global Forecasted Revenue of Human Rabies Immunoglobulin (IM) (2017-2028)
20.3 Global Forecasted Price of Human Rabies Immunoglobulin (IM) (2017-2028)
20.4 Global Forecasted Production of Human Rabies Immunoglobulin (IM) by Region (2017-2028)
20.4.1 North America Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.2 East Asia Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.3 Europe Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.4 South Asia Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.5 Southeast Asia Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.6 Middle East Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.7 Africa Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.8 Oceania Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.9 South America Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.4.10 Rest of the World Human Rabies Immunoglobulin (IM) Production, Revenue Forecast (2017-2028)
20.5 Forecast by Type and by Application (2017-2028)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2017-2028)
20.5.2 Global Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Application (2017-2028)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.2 East Asia Market Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.3 Europe Market Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Countriy
21.4 South Asia Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.5 Southeast Asia Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.6 Middle East Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.7 Africa Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.8 Oceania Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.9 South America Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
21.10 Rest of the world Forecasted Consumption of Human Rabies Immunoglobulin (IM) by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Direct Purchase
Your perfect start with Stats And ResearchWant to customize this report?
This report can be customized according to your requirements. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
Avail PDF Sample Reports
You may also be lnterested in..
Stats And Research Copyright © 2024 .